They included stable (no response / no change) results in their count of positive results. There is no info on tumors that actually shrank in these results. A "stable" tumor is not good.
Normally I would agree, but this stock normally trades much higher on little news and this time we have the insiders onboard.Ed
All they tell you is "Six of 8 (75%) evaluable melanoma patients had stable disease or better".Stable tumor IS NOT GOOD. Why only 8 patients in trial? Why not share the rate of improvement if there is any?Be careful here!
One more question....They said "Four of the 8 patients continue to receive TH-302 after receiving TH-302 for 2.6 to 6.2 months"Why did 4 of the 8 trial patients stop treatment? Does not sound good at all. I'm watching this one for a pump and dump. Insiders bought stock and then publish this ridiculous nonsense that really gives you no real information? Very interesting.